Hexiris Inc.
↗Dieppe, Canada
Hexiris is a Canadian medtech company dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS). The company is developing a first-of-its-kind, patented injectable ocular implant designed to be performed as an office-based procedure under a slit lamp, eliminating the need for traditional operating room settings.
By shifting glaucoma surgery from the operating room to the office, Hexiris aims to improve patient access, reduce healthcare system costs, and address the surgical capacity challenges posed by an aging population. The company is actively building its scientific committee and board with renowned ophthalmologists and industry experts to support its regulatory and commercialization path.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
FUNDING
Stage:Early-stage
PIPELINE
Stage:Preclinical
Lead Drug Stage:Development/Pre-regulatory
Modalities:Medical Device, Ocular Implant
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Scientific Committee includes Dr. Ike Ahmed and Dr. Paul Harasymowycz
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Dr. Houfar Sekhavat - Co-Founder, Chairman and Co-CEO
Dr. Nir Shoham-Hazon - Co-Founder, Co-CEO and CSO
Jean-Philippe Gravel - Co-Founder and COO
Scientific Founders:Dr. Houfar Sekhavat, Dr. Nir Shoham-Hazon
Board Members:Paul Sowyrda, Steven Schiffman
LINKS
Website:hexiris.ca
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Hexiris Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Hexiris Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.